iRhythm Holdings (NASDAQ: IRTC) seeks approval for 2026 equity plan, elects nine directors
iRhythm Holdings (NASDAQ: IRTC) is seeking stockholder approval for its 2026 Equity Incentive Plan, which requests a reserve of 1,690,000 shares and will replace the expiring 2016 plan. The company also announced the election of nine directors for one-year terms at its virtual 2026 Annual Meeting scheduled for May 27, 2026. The proxy statement highlights iRhythm's strong 2025 financial performance, including $747.1 million in revenue and its first positive quarterly GAAP net income in Q4 2025, and details its corporate governance, compensation practices, and a proposed amendment to its Restated Certificate of Incorporation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) regarding potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to connect and assist with the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to restore investor capital and ensure corporate accountability.
Wearable Cardiac Devices Market Overview, Key Trends, and Insights on Leading Companies
The wearable cardiac devices market is projected to reach $13.42 billion by 2030, growing at an 18.8% CAGR, fueled by technological advancements, increased health awareness, and remote monitoring trends. Key players like Apple, Samsung, and Medtronic are driving innovation, with advanced AI-enabled ECG patches and strategic acquisitions shaping the market. The market is segmented by product type, application, distribution channel, and end-user, indicating diverse growth opportunities.
iRhythm Technologies Stock: Strong Growth Momentum in Ambulatory Cardiac Monitoring Amid Expansion Challenges
iRhythm Technologies is demonstrating strong revenue growth in the ambulatory cardiac monitoring sector, driven by its Zio platform and expansion into primary care. The company leverages AI-enhanced wearables and integrates with EHR systems, positioning it as a key player for North American investors despite facing risks like reimbursement pressures and ongoing losses due to scaling investments. Its focus on services over devices and market share gains in primary care highlight its competitive edge.
iRhythm Technologies Stock: Strong Growth Momentum in Ambulatory Cardiac Monitoring Amid Expansion Challenges
iRhythm Technologies (NASDAQ: IRTC) is experiencing robust revenue growth fueled by its Zio platform and expansion into primary care, making its shares a watchlist candidate for North American investors. The company's AI-enhanced wearable biosensors are reshaping cardiac diagnostics, with strong volume growth and penetration into primary care settings. Despite potential risks like reimbursement pressures and competition, iRhythm's innovative technology and focus on services position it favorably in the expanding ambulatory cardiac monitoring market.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of iRhythm Technologies, Inc. (IRTC) stockholders who purchased securities before January 11, 2022. The investigation concerns alleged corporate wrongdoing by iRhythm and its officers/directors. The firm encourages affected investors to contact them to assist with the investigation at no cost.
Why (IRTC) Price Action Is Critical for Tactical Trading
This article provides an AI-driven analysis of Irhythm Technologies Inc. (NASDAQ: IRTC) for tactical trading. It highlights neutral near and mid-term readings, a potential breakdown, and elevated downside risk due to the absence of additional long-term support. The analysis offers specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
iRhythm presents data on arrhythmia detection in CKM patients By Investing.com
iRhythm Holdings, Inc. presented data from three retrospective analyses at the American College of Cardiology 2026 Annual Scientific Sessions, demonstrating the effectiveness of its Zio ambulatory ECG monitoring service in detecting arrhythmias across various cardiovascular-kidney-metabolic patient populations. The company, valued at $3.82 billion with $747 million in revenue, announced findings showing a high prevalence of actionable arrhythmias in patients with chronic kidney disease and obesity. Despite being unprofitable, iRhythm recently reported strong fourth-quarter results and announced leadership changes and a new educational platform.
Studies found frequent arrhythmias in diabetes, kidney and obesity patients
iRhythm Holdings (IRTC) announced new data from retrospective analyses presented at ACC.26, demonstrating a high prevalence of clinically actionable arrhythmias in patients with cardiometabolic and kidney-metabolic (CKM) conditions, including diabetes and obesity. The studies, utilizing iRhythm's Zio ambulatory ECG portfolio, found arrhythmias in 48% of CKD patients and 47% of patients with both diabetes and CKD, and a significantly increased risk of atrial fibrillation with severe obesity. iRhythm also launched iRhythm Academy for clinician education and updated its MyZio app with Spanish language support, while emphasizing the company's leadership in scaling AI in cardiology.
IRhythm team at ACC26 coincides with iRhythm Technologies stock loss amid persistent bearish momentum
iRhythm Technologies (IRTC) saw a 3.83% stock loss, trading at $118.10, despite its team attending the ACC26 event. Technical indicators suggest persistent bearish momentum, with the stock trading well below its major moving averages and a low probability of a near-term price recovery. The price is consolidating between $112.00 and $124.00, with further downside risk if it breaks below $112.00.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of iRhythm Technologies, Inc. (NASDAQ:IRTC) shareholders who purchased securities before January 11, 2022, and continue to hold them. The investigation focuses on whether iRhythm's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information and to assist in the investigation.
iRhythm Technologies Stock: Analyzing Growth Drivers and Investor Opportunities in Cardiac Monitorin
iRhythm Technologies is a leader in wearable cardiac monitoring, offering its Zio platform for detecting cardiac arrhythmias. The company shows strong revenue growth due to high demand for remote diagnostics and expansion into international markets, as well as favorable reimbursement dynamics. While competition and policy changes pose risks, iRhythm's innovation, AI integration, and high patient compliance position it as a resilient performer in healthcare.
iRhythm Technologies Stock: Analyzing Growth Drivers and Investor Opportunities in Cardiac Monitorin
iRhythm Technologies is a leader in wearable cardiac monitoring through its Zio platform, demonstrating strong revenue growth driven by increasing demand for remote diagnostics. North American investors should consider the company's international expansion and reimbursement dynamics as key catalysts for future performance. The company's innovative Zio XT patch offers continuous ECG monitoring, utilizing AI algorithms to detect arrhythmias, and is well-positioned in a rapidly growing market for digital health and remote patient monitoring.
Assenagon Asset Management S.A. Grows Stock Position in iRhythm Technologies $IRTC
Assenagon Asset Management S.A. has significantly increased its stake in iRhythm Technologies, growing its position by 189.2% in Q4 to 225,205 shares, valued at approximately $39.96 million. Despite beating Q4 earnings expectations with EPS of $0.29 and revenue of $208.9 million, iRhythm remains an unprofitable company. Analysts maintain a "Moderate Buy" rating with an average target price near $209.46, even as company insiders sold shares worth about $12.7 million in the last quarter.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm encourages investors who purchased iRhythm securities before January 11, 2022, and still hold them, to connect with their firm to assist in the investigation. The investigation focuses on whether the company and its officers/directors engaged in misconduct, with the firm operating on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. (IRTC) securities. The firm encourages investors who bought iRhythm shares prior to January 11, 2022, and still hold them, to contact them to assist with the investigation into potential corporate wrongdoing. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.
iRhythm (IRTC) director granted 2,218 RSUs vesting from 2027
iRhythm Holdings director Jason H. Patten was granted 2,218 restricted stock units (RSUs) of common stock, which will vest over several years starting from 2027. Each RSU represents a contingent right to one share of iRhythm's common stock, dependent on his continued service. Following this award, Patten directly holds 4,436 shares/RSUs, as reported in a recent Form 4 filing.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) on behalf of investors who purchased securities before January 11, 2022. The firm alleges corporate wrongdoing by iRhythm officers and/or directors and encourages affected investors to contact them for assistance. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis.
Tudor Investment Corp ET AL Takes Position in iRhythm Technologies $IRTC
Tudor Investment Corp ET AL has acquired 20,000,000 shares of iRhythm Technologies (NASDAQ:IRTC) for approximately $3.44 billion, making it their 10th-largest holding. Despite the company beating Q3 earnings expectations with an EPS of $0.29 and revenue of $208.9M, significant insider selling has occurred, with the CEO and other insiders selling shares totaling about $12.73 million over the past 90 days. Analysts currently have a "Moderate Buy" rating for IRTC with an average price target of $209.46.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (NASDAQ: IRTC). The firm is encouraging investors who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for such securities fraud class actions.
iRhythm Technologies (IRTC) Leads Cardiac Monitoring Market with Zio Device, Freedom Capital Initiates Coverage
iRhythm Technologies is a leader in the cardiac monitoring market, recognized for its innovative Zio device. Freedom Capital has initiated coverage on IRTC, highlighting the company's strong market position and potential for continued growth in the burgeoning cardiac care sector. This coverage indicates increasing investor interest and confidence in iRhythm's technology and business model.
iRhythm Technologies Stock (ISIN: US4627231087) Faces Insider Selling Pressure Amid Strong Earnings
iRhythm Technologies reported strong Q4 2025 results with a 27.1% revenue increase and positive EPS, exceeding expectations. Despite this performance, the stock faces pressure from significant insider selling and analyst price target reductions. The company's Zio platform continues to drive growth, though profitability remains a challenge due to heavy investments, and analyst sentiment is a "Moderate Buy" with varied price targets.
Holocene Advisors LP Buys 160,186 Shares of iRhythm Technologies $IRTC
Holocene Advisors LP increased its stake in iRhythm Technologies by 51.2% in Q3, purchasing 160,186 additional shares to hold 473,280 shares valued at approximately $81.4 million. Despite the company beating quarterly earnings and revenue expectations, iRhythm remains unprofitable with negative net margin and return on equity, and analysts project a negative EPS for the current fiscal year. Insider selling has also occurred, though the average analyst rating for IRTC is a "Moderate Buy" with an average target price of $209.46.
Jain Global LLC Purchases Shares of 131,092 iRhythm Technologies $IRTC
Jain Global LLC has established a new position in iRhythm Technologies (NASDAQ:IRTC), acquiring 131,092 shares valued at approximately $22.55 million, representing about 0.41% of the company. This comes even as company insiders have been net sellers, with CEO Quentin S. Blackford and Patrick M. Murphy recently selling shares. Despite insider selling, analysts maintain a "Moderate Buy" consensus rating with an average target price of $209.46, following the company's recent beat on quarterly EPS and 27.1% year-over-year revenue growth.
First Light Asset Management LLC Sells 32,256 Shares of iRhythm Technologies $IRTC
First Light Asset Management LLC has reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 17.2%, selling 32,256 shares and now owning 155,099 shares valued at $26.7 million. This move coincides with significant insider selling from the CEO and another insider, totaling 94,509 shares sold this quarter. Despite beating quarterly revenue and EPS estimates, iRhythm Technologies remains unprofitable, though analysts maintain a "Moderate Buy" rating with an average target price of $209.46.
Cinctive Capital Management LP Takes $4.82 Million Position in iRhythm Technologies $IRTC
Cinctive Capital Management LP has acquired a new stake of 28,044 shares in iRhythm Technologies (NASDAQ:IRTC), valued at approximately $4.82 million, as reported in its most recent Form 13F filing. Several other institutional investors also adjusted their holdings in iRhythm Technologies, with notable increases from firms like Arrowstreet Capital Limited Partnership and Goldman Sachs Group Inc. The article also provides details on iRhythm Technologies' stock performance, recent earnings, analyst ratings, and insider trading activities.
Final Deadline Approaching on April 2, 2021: Kessler Topaz Meltzer & Check, LLP Reminds iRhythm Technologies, Inc. Investors of Class Action Lawsuit Deadline
Kessler Topaz Meltzer & Check, LLP is reminding investors of iRhythm Technologies, Inc. that the final deadline to seek appointment as lead plaintiff in a securities fraud class action lawsuit is April 2, 2021. The lawsuit alleges that iRhythm (NASDAQ: IRTC) made misleading statements during the period of August 4, 2020, to January 28, 2021, regarding the impact of new Medicare reimbursement rates on its business. The company's stock price significantly dropped after the Centers for Medicare and Medicaid Services (CMS) finalized reimbursement rates that were much lower than anticipated.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (IRTC). The firm is encouraging iRhythm investors who purchased securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
iRhythm Technologies Receives 'Moderate Buy' Rating from Analysts
iRhythm Technologies (NASDAQ:IRTC) has received a "Moderate Buy" consensus rating from 15 analysts, with an average 12-month price target of $209.46. Analysts are optimistic about the company's Zio patch and digital diagnostics platform, citing its potential for growth in the cardiac monitoring market. Several firms, including Needham & Company and Evercore, have issued positive reports and raised price targets for the medical technology company.
iRhythm Technologies (NASDAQ:IRTC) Receives Average Recommendation of "Moderate Buy" from Analysts
iRhythm Technologies (NASDAQ:IRTC) has garnered an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $209.46. Despite recent insider selling totaling over $12.7 million, the company reported strong Q4 results, surpassing EPS and revenue expectations. However, iRhythm still faces negative net margin and return on equity, with analysts projecting negative full-year EPS.
IRTC - iRhythm Holdings, Inc Latest Stock News & Market Updates
This page provides news and market updates for iRhythm Holdings, Inc. (IRTC), a digital healthcare company specializing in long-term ambulatory cardiac monitoring. It aggregates information on clinical study results, financial performance, product updates for their Zio service, and corporate announcements relevant to investors and clinicians.
Evercore ISI Group Maintains iRhythm Technologies (IRTC) In-Line Recommendation
Evercore ISI Group has reiterated its "In-Line" recommendation for iRhythm Technologies (IRTC) and maintained a price target of $110.00. This suggests the firm believes the stock is currently trading at a fair value relative to its peers and future prospects.
Schroder Investment Management Group Reduces Stake in iRhythm Technologies
Schroder Investment Management Group has reduced its stake in iRhythm Technologies by 25.8% in the third quarter of 2026, selling 56,903 shares and now owning 164,066 shares valued at $27.81 million. This move could indicate a shift in investor sentiment, even though iRhythm Technologies' core cardiac monitoring products remain in high demand.
Digital health firm iRhythm adds Jason Patten to guide AI, predictive care
iRhythm Holdings (NASDAQ: IRTC) has appointed Jason Patten to its Board of Directors, effective March 12, 2026. Patten, currently Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, brings extensive experience in healthcare leadership, strategy, and innovation. His role will be crucial in expanding iRhythm's reach into primary care, advancing its AI and workflow capabilities for predictive care, and driving disciplined growth as the company aims to build a "billion-dollar platform" focused on clinical excellence.
Irhythm Technologies appoints Jason Patten to board
iRhythm Technologies (IRTC) has appointed Jason Patten to its Board of Directors, effective March 12, 2026. Patten, currently Executive Vice President at UnitedHealth Group, brings strategic leadership in healthcare to iRhythm, a digital health company specializing in cardiac monitoring. The appointment supports iRhythm's goals of profitable scaling, broader primary care access, and advancing AI-driven predictive healthcare solutions, as the company works towards building a billion-dollar platform.
iRhythm Holdings Appoints Jason Patten to its Board of Directors
iRhythm Holdings, Inc. announced the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten, Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, brings extensive experience in healthcare strategy, innovation, and strategic partnerships. His appointment is expected to support iRhythm's growth initiatives, including expanding access through primary care and advancing AI capabilities.
iRhythm Holdings Appoints Jason Patten to its Board of Directors
iRhythm Holdings, Inc. announced the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Patten, who is Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, brings extensive strategic leadership experience in healthcare. His appointment is expected to support iRhythm's efforts to scale, expand profitability, and advance its platform towards more proactive and predictive care.
Victory Capital Management Inc. Acquires 18,053 Shares of iRhythm Technologies $IRTC
Victory Capital Management Inc. increased its stake in iRhythm Technologies by 30.1% in the third quarter, acquiring an additional 18,053 shares, bringing its total to 77,952 shares valued at $13.41 million. Despite a recent earnings beat with $0.29 EPS against an expected $0.02 and strong revenue growth, iRhythm Technologies remains unprofitable with negative margins. Insider selling has also occurred, with executives offloading shares, while analysts maintain a "Moderate Buy" consensus.
Mackenzie Financial Corp Sells 274,552 Shares of iRhythm Technologies $IRTC
Mackenzie Financial Corp significantly reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by selling 274,552 shares, retaining 455,261 shares valued at $78.3 million. Despite beating quarterly earnings estimates with $0.29 EPS on $208.9M revenue, iRhythm remains unprofitable, with analysts forecasting a negative EPS for the current year. The stock holds a consensus "Moderate Buy" rating with an average target price of $209.46.
iRhythm Technologies (NASDAQ:IRTC) Price Target Cut to $214.00 by Analysts at Citigroup
Citigroup has lowered its price target for iRhythm Technologies (IRTC) from $242.00 to $214.00, while maintaining a "buy" rating, indicating a potential upside of 75.08%. This adjustment follows similar reductions from other firms like JPMorgan, Baird, and Wells Fargo, bringing the average analyst price target for IRTC to $209.46. Despite beating quarterly earnings expectations with strong revenue growth, the company remains unprofitable, and insiders have recently sold a significant number of shares.
Sands Capital Management LLC Cuts Stake in iRhythm Technologies $IRTC
Sands Capital Management LLC has reduced its stake in iRhythm Technologies by 23.3% in the third quarter of 2025, selling over 679,000 shares but still holding 6.94% of the company's stock, valued at approximately $384.6 million. Despite beating EPS and revenue estimates, iRhythm remains unprofitable, and company insiders have been net sellers, disposing of shares worth about $12.7 million recently. Analysts maintain a "Moderate Buy" rating with a consensus price target of $211.62.
Sands Capital Management Reduces Stake in iRhythm Technologies
Sands Capital Management LLC reduced its stake in iRhythm Technologies (NASDAQ: IRTC) by 23.3% during the third quarter of 2025, selling 679,417 shares. Despite this reduction, attributed to portfolio rebalancing, Sands Capital remains a significant institutional shareholder, owning 6.94% of the company's outstanding stock, valued at $384.6 million. iRhythm Technologies is a leading provider of wearable cardiac monitoring devices and data analytics services.
Capital Research Global Investors Reduces Stake in iRhythm Technologies
Capital Research Global Investors has reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 21.4% during the third quarter of 2026, selling 323,128 shares and retaining 1,183,736 shares, or about 3.67% ownership. This move by a major institutional investor could indicate a shift in market sentiment towards the medical technology company, which specializes in wearable cardiac monitoring devices. Investors will likely be monitoring further changes in institutional ownership for insights into iRhythm's future performance.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (NASDAQ:IRTC) on behalf of investors who purchased securities before January 11, 2022, and currently hold them. The investigation focuses on whether the company's officers or directors engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information and to assist with the investigation, noting that they operate on a contingency fee basis.
iRhythm Technologies $IRTC Shares Sold by Capital Research Global Investors
Capital Research Global Investors significantly reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 21.4% in the third quarter, selling 323,128 shares. Despite this, iRhythm Technologies has a "Moderate Buy" consensus rating from analysts with a target price of $211.62. The company recently reported strong financial results, beating EPS estimates and growing revenue by 27.1% year-over-year.
iRhythm Technologies Experiences Revision in Stock Evaluation Amid Market Volatility
iRhythm Technologies (IRTC) stock has seen significant fluctuations, closing at $127.95, and showing bearish trends across several technical indicators. The company has underperformed the S&P 500 year-to-date, reflecting challenges in the Pharmaceuticals & Biotechnology sector, despite a slight positive return over the last year. This revision in stock evaluation highlights the competitive pressures and market volatility affecting IRTC.
Watch: iRhythm CEO on Proactive Arrhythmia Monitoring
The article features an interview with the CEO of iRhythm, discussing proactive monitoring for arrhythmia. The content highlights iRhythm's efforts in improving cardiac care through advanced technology. It promotes a video discussion on the topic of arrhythmia monitoring.
Avoiding Lag: Real-Time Signals in (IRTC) Movement
This article from Stock Traders Daily discusses the real-time signals for iRhythm Technologies Inc. (IRTC), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It provides specific institutional trading strategies including long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and notes current elevated downside risk.
iRhythm closes offering worth more than $660M
iRhythm (Nasdaq: IRTC) announced the closure of a senior notes offering, generating gross proceeds of $661.25 million. The cardiac monitor manufacturer initially intended to offer $450 million in convertible senior notes, upsized it to $575 million, and included the full exercise of an option for an additional $86.25 million. The net proceeds of approximately $643 million will be used for capped call transactions, repayment of existing debt, share repurchases, and general corporate purposes such as sales, marketing, and R&D.
iRhythm Technologies, Inc. (NASDAQ:IRTC) Q4 2025 earnings call transcript
This document is a transcript of the iRhythm Technologies, Inc. (NASDAQ:IRTC) Q4 2025 earnings call. It provides detailed insights into the company's financial performance and operational updates for the specified quarter, as discussed by management and analysts during the call.
